Author

Alan Lau

AstraZeneca (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:rat· 1

Frequent Co-Authors

Aaron SmithiD· 1 shared Anderson T. WangiD· 1 shared Andres Tellez· 1 shared Claire Sadler· 1 shared Elaine B. CadoganiD· 1 shared Gareth Hughes· 1 shared Jennifer Barnes· 1 shared Lenka Oplustil O’ConnoriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron SmithORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Gap scheduling of a PARP inhibitor and nanoparticle TOP1 agent combination avoids synergistic bone marrow toxicity

Lenka Oplustil O’Connor, Anderson T. Wang, Claire Sadler, Jennifer Barnes, Rajesh Odedra, Aaron Smith, Gareth Hughes, Alan Lau, Andres Tellez, Scott D. Eliasof, Elaine B. Cadogan, Mark J. O’Connor

The paper identifies a gap schedule for combining a PARP inhibitor and a tumor-targeted nanoparticle chemotherapy to enhance efficacy while reducing bone marrow toxicity.

bioRxiv · Apr 30, 2025 · PreprintCancer Biology